StockTipsArenaBeta

BUY Morepen Laboratories Limited — Nilesh Jain, Centrum Broking

BUYMorepen Laboratories Limited
Morepen Laboratories share price target & all analyst calls

byNilesh Jain, Centrum BrokingHorizon: NA (inferred Swing (≤2wk))1 Oct 2026via Zee Business (Live)

Entry₹128Stated
Target₹135
Total upside +5.47%
Stop loss₹125.5-1.95% risk
CMP₹133.72Just now
Active+4.47%+0.96%upside left 14d left
Follow Nilesh Jain for new calls(32% target hit, 133 closed calls)Get alertsWatch MOREPENLAB for new buy/sell callsGet alertsSee 1 other Swing call on MOREPENLABSee 161 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 1 Oct, 4:01 pm IST
3 supporting1 opposing
Supports the BUY call (3)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·1 Oct · today

Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA, marking a significant step in expanding its integrated CDMO capabilities.

NSE · Press Release·28 Sept · 3d ago

(opens in new tab)

Morepen Laboratories has submitted its first Abbreviated New Drug Application (ANDA) to the U.S. FDA for Sitagliptin Tablets, marking an expansion into integrated finished dosage development.

BSE · Company Update·28 Sept · 3d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·1 Oct · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.